Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Bone-Metastasis Microenvironment May Explain Immunotherapy Resistance

DOI: 10.1158/2159-8290.CD-RW2019-174 Published January 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Anti-CTLA4 caused Th1 expansion in primary prostate-cancer tumors, but not bone metastases.

  • Concept: Anti-CTLA4 plus anti–TGFβ was more effective in treating bone metastases than either alone in mice.

  • Impact: Bone metastases’ microenvironment may explain their resistance to immune-checkpoint blockade.

The use of immune-checkpoint blockade (ICB) is effective in some patients with metastatic castration-resistant prostate cancer (CRPC), but efficacy in patients with bone metastases is limited. In paired pre- and post-treatment primary prostate tumors and bone marrow samples from the same patients, Jiao and colleagues found that anti-CTLA4 (specifically, ipilimumab) treatment caused Th1 expansion in the prostate tumors, but not in the bone marrow, which instead exhibited an increase in cells of the Th17 lineage. Treatment with anti-CTLA4 and anti–PD-1 caused tumor regression and improved overall survival in mice injected subcutaneously with prostate-cancer cells but had little effect on prostate-cancer cells injected into the bones despite triggering an expansion of tumor-infiltrating T cells in both models. In the bone CRPC model, the CD4+ T-cell population was composed solely of regulatory T cells (Treg) and Th17 cells, and the population of the latter increased after ICB treatment. Notably, Th1 effector cells were lacking in the bone CRPC tumors, which may explain the inferior response of these tumors to ICB. Compared with bone marrow from tumor-free femurs, bone marrow from tumor-bearing femurs had increased TGFβ1 levels, which may have resulted from an observed increase in osteoclast-mediated bone resorption. In the mouse bone CRPC model, combination treatment with anti-CTLA4 and anti-TGFβ reduced tumor growth and improved overall survival more than either treatment alone, and the combination treatment resulted in an increase in Th1 cells and a decrease in Tregs in the tumor-infiltrating T-cell population. Further experiments revealed that the combination treatment caused a clonal expansion of tumor-specific CD8+ T cells, most of which exhibited a memory–effector signature. Together, these findings suggest that TGFβ-mediated restriction of development of the Th1 lineage along with insufficient expansion and activation of CD8+ T cells may be responsible for the resistance of CRPC bone metastases to ICB. Additionally, this study demonstrates that combination therapy with ICB and anti-TGFβ may be worth investigating.

Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell 2019;179:1177–90.e13.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 10 (1)
January 2020
Volume 10, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bone-Metastasis Microenvironment May Explain Immunotherapy Resistance
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bone-Metastasis Microenvironment May Explain Immunotherapy Resistance
Cancer Discov January 1 2020 (10) (1) 13; DOI: 10.1158/2159-8290.CD-RW2019-174

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bone-Metastasis Microenvironment May Explain Immunotherapy Resistance
Cancer Discov January 1 2020 (10) (1) 13; DOI: 10.1158/2159-8290.CD-RW2019-174
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Prostate Cancer

  • Developmental Programs Are Reactivated in Prostate Cancer Metastasis
  • Remaining Prostate Luminal Cells Regenerate after Androgen Deprivation
  • DDR-Defective Metastatic Prostate Cancers Are Susceptible to Olaparib
Show more Prostate Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement